The funding will come from the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) in partnership with the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense and Army Contracting Command (JPEO-CBRND).
Corning will use the funding to expand its capacity for manufacturing advanced pharmaceutical glass tubing and vials in the US.
The company will continue to increase its pharmaceutical tubing manufacturing capacity in Vineland, New Jersey, and its vial production capacity in Durham, North Carolina.
BARDA’s funding is intended to support the healthcare industry in addressing present and future public health challenges, as well as bolster the domestic pharmaceutical supply chain by increasing manufacturing efficiency.
Corning Pharmaceutical Technologies vice-president and general manager Brendan Mosher said: “Corning’s pharmaceutical glass packaging has played a critical role in ensuring the safe and on-time delivery of critical medications.
“Our Valor Glass and Velocity Vials are some of the strongest, fastest to fill, and highest-quality pharmaceutical glass vials available.
“Our products play a critical role in helping to protect patients by improving glass quality, lowering the risk of contamination, and helping to accelerate the delivery of lifesaving treatments.”
The investment comes after BARDA committed to providing $204m of funding to Corning in June 2020.
The previous funding was intended to expand the company’s domestic capacity for manufacturing Corning Valor Glass vials to expedite the delivery of Covid-19 vaccines.
Based in Corning, New York, Corning specialises in speciality glass, ceramics and related materials and technologies.
The company’s solutions are designed primarily for industrial and scientific applications.
In May 2020, Corning signed an agreement to supply its Valor Glass vials to pharmaceutical company Pfizer.